Reference

Results of first-phase experiments with the new antiarrhythmic propafenone

Results of first-phase experiments with the new antiarrhythmic propafenone. Onodera, Takeo; Kobayashi, Yoshinori; Hung, Chi Chao; Saito, Hiroyasu; Ino, Takeshi; Arata, Hiroji; Munekata, Kazuo; Kato, Yoshio; Aramaki, Takaki; et al. (Nippon Med. Sch., Tokyo, Japan). Rinsho Yakuri, 15(1), 123-4 (Japanese) 1984. CODEN: RIYADS. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Propafenone (I) [54063-53-5] given to healthy subjects at 100-300 mg produced no significant side effects, although repeated administration for 7 days slightly prolonged the PR period and the QRS amplitude in the ECG.

The cardiovascular system and propafenone

The cardiovascular system and propafenone. Experimental studies in dogs. Rossi, F.; Montinaro, C.; Persico, N.; Guarino, V.; Chieppa, S.; Del Gaudio, F.; Silvestri, G. (I Fac. Med. Chir., Univ. Napoli, Italy). Riv. Eur. Sci. Med. Farmacol., 5(4), 621-4 (Italian) 1983. CODEN: RESFDJ. ISSN: 0392-291X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) When given by various routes to anesthetized dogs, propafenone (I) [54063-53-5] had extraneous effects on the cardiovascular system only at doses greater than those required for its pharmacol. antiarrhythmic activity.